[1333] Extracavitary KSHV+ Large B-Cell Lymphoma: Time To Have a New Name?
Zenggang Pan, Zhengbin Lu, Lanting Liu, David B Wilson, Vishnu Reddy, Huanyou Wang, Yongsheng Ren. Univ. of Alabama at Birmingham; Ameripath, Indianapolis, IN; Univ. of California San Diego
Background: Extracavitary Kaposi sarcoma-associated herpesvirus (KSHV)+ large B-cell lymphoma (EK-LBL) has rarely been observed without effusions. It is uncertain whether it should be considered as a separated entity or a variant of primary effusion lymphoma (PEL). The diagnosis of EK-LBL can be challenging due to lack of a clear definition and a consensus diagnostic term. Here, we reviewed 46 such cases with emphasis on the clinicopathologic features.
Design: 46 EK-LBL cases were collected from the English literature (42) or our files (4). All cases had no effusions before or after presentation. Special studies of our cases included immunostains [CD45, CD20, CD79a, PAX5, CD3, MUM1, EMA, CD30, CD138, immunoglobulin (Ig) light chains, and KSHV], EBV(EBER), and T-cell receptor and Ig gene rearrangements. The results were compared with those summarized from 95 PELs in the literature.
| EK-LBL | Classical PEL | |||
|---|---|---|---|---|
| Gender (male/female) | 45:1 | 86:1 | ||
| HIV | 44/46 | 96% | 87/95 | 92% |
| KSHV | 46/46 | 100% | 61/61 | 100% |
| EBER | 32/42 | 76% | 26/40 | 65% |
| CD45 (LCA) | 29/38 | 76% | 65/69 | 94% |
| CD20 | 9/46 | 20% | 4/75 | 5% |
| CD79a | 8/31 | 26% | 0/13 | 0% |
| Ig kappa | 4/30 | 13% | 7/33 | 21% |
| Ig lambda | 10/32 | 32% | 7/33 | 21% |
| CD138 | 22/31 | 70% | 20/33 | 61% |
| MUM1 | 10/10 | 100% | 12/12 | 100% |
| CD30 | 20/34 | 59% | 39/56 | 70% |
| EMA | 13/22 | 59% | 22/29 | 76% |
| IgH rearrangement | 15/17 | 88% | 30/42 | 71% |
